Gilead extends Arcellx tender offer to April 27 after regulatory clearances
PUBT · 04/17 12:30
Share
Listen to the news
- Acquisition of Arcellx by Gilead cleared all required competition reviews, leaving only a 14-day Australian waiting period set to end April 27, 2026 at 10:00 a.m. ET.
- Tender offer expiration extended to April 27, 2026 at 5:00 p.m. ET.
- Offer terms unchanged at USD 115 per Arcellx share in cash.
- Deal also includes 1 contingent value right per share, paying USD 5 on March 31, 2030 if cumulative worldwide anito-cel sales exceed USD 6 billion by Dec. 31, 2029.
- About 10,271,823 shares were tendered as of April 16, 2026, representing 17.5% of Arcellx shares outstanding at that time.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604170830BIZWIRE_USPR_____20260417_BW916113) on April 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved